Center for Immunization Research (CIR)
Leaders in vaccine development, research and education since 1985.
Welcome to the Center for Immunization Research
CIR was founded to facilitate the development of new vaccines against infectious diseases of global importance. Here you can find the latest evidence-based updates about vaccines, learn about clinical studies, read journal articles by our infectious disease experts, and more.
Our Research
Join a clinical study
Project SAVE (Support a Vaccine Effort) is the adult recruitment program at the Center for Immunization Research. The program is used to screen adult potential study participants to help determine their eligibility for specific clinical vaccine studies at the CIR.
New and Noteworthy
Next-gen leaders in diarrheal disease: Q&A with Brittany Feijoo
Brittany Feijoo, MSN, FNP-BC, a research associate at the Johns Hopkins Bloomberg School of Public Health, is one of those next-generation leaders. We talked to Brittany about her path from nursing to global health, her research on Shigella in Kenya, and her role models both inside and outside the scientific community.
Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children
In high-income and middle-income countries, two new products have been authorized to prevent RSV in infants. These products are not yet available in low-income and lower-middle-income countries, where most RSV deaths occur. This paper briefly reviews the efficacy, effectiveness, and safety of these products and explores potential pathways to broadening their availability.
We've Moved!
The CIR's East Baltimore location has moved to the Rangos Building!
Effective May 28, 2024 our new address is:
855 N. Wolfe Street Suite 601
Baltimore, MD 21205
Hampton House Farewell Celebration
The Johns Hopkins community came together for a bittersweet celebration of Hampton House. The building, slated for demolition to make way for a new state-of-the-art facility has been a fixture on campus for almost 100 years.
Phase 3 Study Results for Tetravalent Dengue Vaccine Published in NEJM
Study results for a phase 3 trial titled: "Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults" were published on February 1, 2024 in the New England Journal of Medicine. CIR's Team FIRE conducted more than 30 trials for the development of the Butantan Dengue Vaccine (Butantan-DV) used in this study. The study was conducted at 16 sites in Brazil and showed that Butantan-DV prevented symptomatic dengue virus 1 and dengue virus 2 through 2 years of follow up.
Scientists deliberately gave women Zika — here’s why
Findings from a challenge study conducted by CIR's Team FIRE indicate that the two strains of Zika administered in the trial can be safely and effectively used to infect participants in a Zika vaccine trial.
Meet our Faculty
Our dedicated faculty members work together to carry out CIR’s mission by applying public health expertise to their individual infectious diseases areas of interest. Learn more about their important work on the BSPH faculty pages.
Anna Durbin, MD, studies experimental vaccines for SARS-CoV-2, dengue, West Nile, Zika, malaria, and more in human clinical trials and in controlled human infection studies.
Support our Research
Your financial gift can both support our important immunization research and help us combat misinformation about vaccines